Hypersensitivityįrequency not reported: Anaphylactoid reactions, drug reaction with eosinophilia and systemic systems (DRESS) CardiovascularĬommon (1% to 10%): Thrombophlebitis (after IV infusion) The patient met the diagnostic criteria for drug-induced Sweet's syndrome and clindamycin was the most likely cause due to the timeline of antibiotic therapy and the patient's improvement following its discontinuation. Two days later, the rash improved considerably. The lesions progressed and the patient's antibiotic therapy was discontinued. Three days after starting oral clindamycin for the persistence of symptoms following a root canal, a 34-year-old male patient reported " pimples" on his scalp which changed to pustules 24 hours later. Drug-induced Sweet's syndrome was determined based on the temporal relationship of the patient's symptoms, the beginning and end of clindamycin therapy, and the exclusion of other etiologies. Following discontinuation of clindamycin, the patient's symptoms resolved over several days. The patient's symptoms persisted despite tooth extraction and continuance of antibiotic treatment with intravenous, then oral, clindamycin. The patient's symptoms developed 2 days after initiating oral clindamycin therapy for a tooth infection. Rash was particularly common in AIDS patients.Ī 47-year-old female patient with multiple comorbidities was diagnosed with Sweet's Syndrome. Postmarketing reports: Serious cutaneous adverse reaction Rare (less than 0.1%): Erythema multiforme, pruritusįrequency not reported: Toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, bullous dermatitis, generalized mild to moderate morbilliform-like rash, acute generalized exanthematous pustulosis (AGEP), Sweet's Syndrome Pseudomembranous colitis may also be associated with toxic megacolon, which can be life-threatening.Īn unpleasant or metallic taste has occasionally been reported after high doses of IV clindamycin. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment and is associated with the presence of Clostridium difficile toxin in the stool. Uncommon (0.1% to 1%): Dysgeusia, nausea, vomitingįrequency not reported: Esophageal ulcers, esophagitis (oral preparations) GastrointestinalĬommon (1% to 10%): Pseudomembranous colitis, diarrhea, abdominal pain thick, white vaginal discharge with no odor or with a mild odorĪpplies to clindamycin: compounding powder, injectable solution, intravenous solution, oral capsule, oral powder for reconstitution.sores, ulcers, or white spots in the mouth or on the lips.red skin lesions, often with a purple center.rash with flat lesions or small raised lesions on the skin.puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue.general feeling of tiredness or weakness.dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position.diarrhea, watery and severe, which may also be bloody.blistering, peeling, or loosening of the skin.Abdominal or stomach cramps, pain, or tenderness.Although not all of these side effects may occur, if they do occur they may need medical attention.Ĭheck with your doctor immediately if any of the following side effects occur while taking clindamycin: Rare Serious side effects of ClindamycinĪlong with its needed effects, clindamycin may cause some unwanted effects. Because clindamycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate. If CDAD is confirmed or suspected, antibiotic therapy not directed against Clostridium difficile may need to be discontinued. It is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of therapy with clindamycin.Ĭlostridium difficile associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to life-threatening colitis and has been observed to begin over 2 months after the administration of antibacterial agents. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild to life-threatening.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |